Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris - Trial NCT06403501
Access comprehensive clinical trial information for NCT06403501 through Pure Global AI's free database. This Phase 3 trial is sponsored by Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. and is currently Not yet recruiting. The study focuses on Acne Vulgaris. Target enrollment is 692 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Timeline & Enrollment
Phase 3
May 01, 2024
Feb 01, 2025
Primary Outcome
Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA),Change From Baseline in Non-inflammatory Lesion (NIL) Counts,Change From Baseline in Inflammatory Lesion (IL) Counts
Summary
The primary objective of this study is to determine the safety and efficacy of clascoterone
 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial
 acne vulgaris.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06403501
Non-Device Trial